Skip to content

Released Nov 10, 2021, before the open

10-Q filed Nov 10, 2021, 41 days after period end · 0001785530-21-000054

Q3 2021 · 10-Q
Revenue—
Net Income-$13.76MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.51N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$13,795,000N/M
Operating Cash Flowderived-$12,417,000N/M
Free Cash Flowderived-$12,519,000N/M

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020
Net Income-$13.76M-$6.07M
EPS Diluted-$0.51-$6.61

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR